156 related articles for article (PubMed ID: 16079324)
1. Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients.
Portolés J; Krisper P; Choukroun G; de Francisco AL
Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii13-17. PubMed ID: 16079324
[TBL] [Abstract][Full Text] [Related]
2. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
Carrera F; Disney A; Molina M
Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv19-iv30. PubMed ID: 17526546
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
4. [Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?].
Borrelli S; Baldanza D; Scigliano R; Catapano F; Grimaldi M; Calabria M; Zamboli P; Minutolo R; De Nicola L; Conte G
G Ital Nefrol; 2009; 26(1):31-7. PubMed ID: 19255962
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and renal failure.
Macdougall IC
Curr Hematol Rep; 2003 Nov; 2(6):459-64. PubMed ID: 14561389
[TBL] [Abstract][Full Text] [Related]
6. Dose tailoring strategies in haemodialysis patients: a discussion of case histories.
Kleophas W
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi31-6. PubMed ID: 15958825
[TBL] [Abstract][Full Text] [Related]
7. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
8. Once weekly treatment with epoetin-beta.
Locatelli F
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi26-30. PubMed ID: 15958823
[TBL] [Abstract][Full Text] [Related]
9. [Pure red cell aplasia as a complication of treatment with recombinant human erythropoietin].
Grzegorzewska AE; Sucharzewska-Tomczak M
Pol Merkur Lekarski; 2004 Oct; 17(100):407-9. PubMed ID: 15690716
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents].
Rossert J; Casadevall N
Nephrol Ther; 2006 Sep; 2 Suppl 4():S283-6. PubMed ID: 17373271
[TBL] [Abstract][Full Text] [Related]
11. [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
Miyazaki T; Obana T; Takasaki H; Tanaka M; Yamaji S; Fujimaki K; Fujita H; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2007 May; 48(5):391-6. PubMed ID: 17571584
[TBL] [Abstract][Full Text] [Related]
12. The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia.
Summers S; Holdsworth S; Sharples E
Nephrol Dial Transplant; 2008 Oct; 23(10):3053-5. PubMed ID: 18558625
[No Abstract] [Full Text] [Related]
13. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
Opatrný K
Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
[TBL] [Abstract][Full Text] [Related]
14. The effect of subcutaneous recombinant human erythropoietin (r-Hu EPO) in CAPD patients with renal anaemia.
Janicka L; Ksiazek A; Baranowicz I; Mierzicki P
Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():67-77. PubMed ID: 8192534
[TBL] [Abstract][Full Text] [Related]
15. Epoetin-induced pure red cell aplasia successfully treated with androgens.
Sánchez de la Nieta MD; Caparrós G; Rivera F
J Nephrol; 2006; 19(2):220-1. PubMed ID: 16736425
[TBL] [Abstract][Full Text] [Related]
16. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients.
Kwan JT; Pratt RD;
Curr Med Res Opin; 2007 Feb; 23(2):307-11. PubMed ID: 17288685
[TBL] [Abstract][Full Text] [Related]
17. [Pure red-cell anemia due to recombinant human erythropoietin and its status in oncology practice].
Lehoczky O
Magy Onkol; 2004; 48(2):163-6. PubMed ID: 15351813
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of erythropoietin-associated pure red cell aplasia.
Carson KR; Evens AM; Bennett CL; Luminari S
Best Pract Res Clin Haematol; 2005; 18(3):467-72. PubMed ID: 15792921
[TBL] [Abstract][Full Text] [Related]
19. Immunologic mechanisms of EPO-associated pure red cell aplasia.
Schellekens H
Best Pract Res Clin Haematol; 2005; 18(3):473-80. PubMed ID: 15792922
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
